Background And Objectives: To functionally evaluate the efficacy of glatiramer acetate (Cop-1) as a neuroprotective treatment for laser-induced retinal injuries in rats.
Study Design/materials And Methods: Using standard lasering and flash ERG techniques, we evaluated the effect of photocoagulation and of Cop-1 treatment on retinal function 3, 20, and 60 days after covering one-half of the retina with of 23 rats with argon laser lesions.
Results: Significant neuroprotective effects of Cop-1 treatment on functional recovery were observed 20 and 60 days after retinal photocoagulation. Two months post-lasering, the amplitude of electroretinographic signals in lasered eyes (mean+/-SEM) was 99.5+/-10.2% of that of intact eyes in the Cop-1-treated group and 85.8+/-5.5% in the untreated lasered control group (P<0.05).
Conclusions: Cop-1 immunization in rats is neuroprotective against laser-induced injuries to the outer retina and improves functional recovery of the injured retina. Studies have documented effective neuroprotective treatment after laser damage to myelinated neurons, but this is the first report of neuroprotection of nonmyelinated neurons.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/lsm.20610 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antimicrobial peptide glatiramer acetate targets Pseudomonas aeruginosa lipopolysaccharides to breach membranes without altering lipopolysaccharide modification.
NPJ Antimicrob Resist
February 2024
National Heart and Lung Institute, Imperial College London, London, UK.
Antimicrobial peptides (AMPs) are key components of innate immunity across all domains of life. Natural and synthetic AMPs are receiving renewed attention in efforts to combat the antimicrobial resistance (AMR) crisis and the loss of antibiotic efficacy. The gram-negative pathogen Pseudomonas aeruginosa is one of the most concerning infecting bacteria in AMR, particularly in people with cystic fibrosis (CF) where respiratory infections are difficult to eradicate and associated with increased morbidity and mortality.
View Article and Find Full Text PDFCost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
J Neurol
January 2025
Department of Neurology, Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Background: Natalizumab (NAT) is an established disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, its use involves complex decision-making, often leading to initial use of lower efficacy therapies. Recently, the first biosimilar NAT was approved, enabling competitive pricing.
View Article and Find Full Text PDFEfficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies.
Mult Scler Relat Disord
January 2025
Department of Nutrition and Drug Research, Faculty of Health Sciences, Institute of Public Health, Jagiellonian University Medical College, Skawińska Street 8, 31-066 Krakow, Poland. Electronic address:
Objective: This study aimed to review the efficacy and safety profile of disease-modifying therapies (DMTs) in patients with relapsing pediatric-onset multiple sclerosis (POMS).
Methods: A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Published randomized controlled trials (RCTs), nonrandomized studies with a control group, large single-arm studies, and ongoing (unpublished) studies investigating the use of approved and unapproved DMTs in POMS were included.
COVID-19 in patients with multiple sclerosis-A narrative review.
Mult Scler Relat Disord
December 2024
University of Miami Miller School of Medicine, Miami, FL, United States.
Background: Multiple sclerosis (MS) is a complex neurodegenerative disease characterized by immune dysregulation, affecting over 2.5 million people worldwide. Interestingly, COVID-19 infection can cause neurodegeneration through demyelination similar to that of MS, and COVID-19 infection can lead to long-term neurological sequelae, post-COVID-19 neurological syndrome.
View Article and Find Full Text PDFMultiple sclerosis disease-modifying therapy use in the department of veteran affairs and Medicare: A comparative analysis.
Mult Scler Relat Disord
December 2024
Oregon Health & Science University, Portland, OR, USA; VA Portland Medical Center, Portland, OR, USA.
Background: High-cost disease-modifying therapies (DMT) for multiple sclerosis (MS) have created affordability challenges for people with MS (PwMS) and payers. The Department of Veterans Affairs (VA) is the largest integrated healthcare system in the US and uses a variety of approaches to manage utilization and cost of MS DMT. The objective of this paper is to compare national utilization trends in the VA to the US Medicare program, another large federal public healthcare program.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!